Current understanding of the molecular mechanisms of kidney cancer: A primer for urologists

Journal of the Canadian Urological Association

Volumn 1, Issue 2 SUPPL, 2007, Pages

  Lim, Darwin L ^a   Ko, Raymond ^a   Pautler, Stephen E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449406703     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Maclaughlin J, Dryer D, Logan H, et al. Canadian cancer society/National Cancer Institute of Canada: Canadian cancer statistics 2006. Toronto: Canada; 2006.
2. Kovacs G, Akhtar M, Beckwith BJ, et al. Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-3.
3. Collins E. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc U K 1894;14: 141-9.
4. Maher ER, Kaelin WG. von Hippel-Lindau disease. Medicine 1997;76:381-91.
5. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22:4991-5004.
6. Iliopoulos O, Kibel A, Gray S, et al. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
7. Chen F, Kishida T, Duh FM, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995;55:4804-7.
8. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature1988;332:268-9.
9. Latif F, Tory K, Gnarra J, et al. Identification of von Hippel-Lindau disease tumor sup-pressor gene. Science 1993;260:1317-20.
10. Ye Y, Vasavada S, Kuzmin I, et al. Subcellular localization of the von Hippel-Lindau dis-ease gene product is cell cycle-dependent. Int J Cancer 1998;78:62-9.
11. Lee S, Chen DY, Humphrey JS, et al. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A 1996;93:1770-5.
12. Lee S, Neumann M, Stearman R, et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor pro-tein. Mol Cell Biol 1999;19:1486-97.
13. Duan DR, Humphrey JS, Chen DY, et al. Characterization of the VHL tumor suppres-sor gene product: localization, complex formation, and the effect of natural inactivat-ing mutations. Proc Natl Acad Sci U S A 1995;92:6459-63.
14. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor sup-pressor protein. Mol Cell Biol 2002;22:5319-36.
15. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
16. Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor sup-pressor protein to Elongin B and C. Science 1995;269:1444-6.
17. Takagi Y, Pause A, Conaway RC, et al. Identification of Elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein. J Biol Chem1997; 272:27444-9.
18. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene prod-uct forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997;94:2156-61.
19. Lonergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes con-taining elongins B/C and Cul2. Mol Cell Biol 1998;18:732-41.
20. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor sup-pressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
21. Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconsti-tuted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000;97:10430-5.
22. Wang GL, Jiang B-H, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
23. Srinivas V, Zhang LP, Zhu XH, et al. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 1999;260:557-61.
24. Masson N, William C, Maxwell PH, et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-206.
25. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactiva-tion domain: a hypoxic switch. Science 2002;295:858-61.
26. Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A 1991;88:5680-4.
27. Chen C, Pore N, Behrooz A, et al. Regulation of glut 1 mRNA by hypoxia-inducible factor-1.Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-25.
28. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhy-drase in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgene. Proc Natl Acad Sci U S A 1998;95:12596-601.
29. Tureci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning expres-sion and chromosomal localization of a carbonic anhydrase gene that is overex-pressed in some renal cell cancers. Proc Natl Acad Sci U S A 1998;95:7608-13.
30. Mukhopadhyay D, Knebelmann B, Cohen HT, et al. The von Hippel-Lindau tumor sup-pressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
31. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothe-lial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-94.
32. Knebelmann B, Ananth S, Cohen HT, et al. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-31.
33. Mack FA, Rathmell WK, Arsham AM, et al. Loss of pVHL is sufficient to cause HIF dys-regulation in primary cells but does not promote tumor growth. Cancer Cell2003;3:75-88.
34. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF-1 alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell2002;1: 247-55.
35. Jiang Y, Zhang W, Kondo K, et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 2003;1: 453-62.
36. Wykoff CC, Pugh CW, Maxwell PH, et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000;19:6297-305.
37. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, et al. von Hippel-Lindau tumor suppres-sor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res 2006;66:1553-60.
38. Ohh M, Yauch R, Lonergan M, et al. The von Hippel-Lindau tumor suppressor pro-tein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell1998; 1:959-68.
39. Esteban-Barragan MA, Avila P, Alvarez-Tejado M, et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res 2002;62:2929-36.
40. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
41. Zhou MI, Wang H, Ross JJ, et al. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem 2002;277:39887-98.
42. Feldman DE, Spiess C, Howard DE, et al. Tumorigenic mutations in VHL disrupt fold-ing in vivo by interfering with chaperonin binding. Mol Cell 2003;12:1213-24.
43. Li Z, Wang D, Na X, et al. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J 2003;22:1857-67.
44. Okuda H, Saitoh K, Hirai S, et al. The von Hippel-Lindau tumor suppressor protein medi-ates ubiquitination of activated atypical protein kinase C. J Biol Chem 2001;276: 43611-7.
45. Okuda H, Hirai S, Takaki Y, et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-7.
46. Li Z, Wang D, Na X, et al. Identification of a deubiquitinating enzyme subfamily as sub-strates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun2002; 294:700-9.
47. Li Z, Na X, Wang D, et al. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2002; 277:4656-62.
48. Na X, Duan HO, Messing E, et al. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003;22:4249-59.
49. Roe JS, Kim H, Lee SM, et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006;22:395-405.
50. Bindra RS, Vasselli JR, Stearman R, et al. VHL mediated hypoxia regulation of cyclin D1 in renal cancer cells. Cancer Res 2002;62:3014-9.
51. Osipov V, Keating JT, Faul PN, et al. Expression of p27 and VHL in renal tumors. Appl Immunohistochem Mol Morphol 2002;10:344-50.
52. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8: 348-57.
53. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
54. Hoffman MA, Ohh M, Yang H, et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet2001; 10:1019-27.
55. Clifford SC, Cockman ME, Smallwood A, et al. Contrasting effects on HIF1a regula-tion by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-38.
56. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal carcinoma. J Urol1994;151: 561-6.
57. Zbar B, Glenn G, Lubensky I, et al. Hereditary papillary renal carcinoma clinical studies in 10 families. J Urol 1995;153:907-12.
58. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
59. Brinkmann V, Foroutan H, Sachs M, et al. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573-86.
60. Jeffers M, Rao MS, Rulong S, et al. Hepatocyte growth factor/scatter factor-Met sig-naling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 1996;7:1805-13.
61. Medico E, Mongiovi AM, Huff J, et al. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 1996;7:495-504.
62. Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 1991;66:697-711.
63. Santoro MM, Collesi C, Grisendi S, et al. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol 1996;16:7072-83.
64. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. J Cell Sci 1985;77:209-23.
65. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
66. Faletto DL, Tsarfaty I, Kmiecik TE, et al. Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene 1992;7:1149-57.
67. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET protooncogene is activated by autophosphorylation. Mol Cell Biol 1991;11:1793-803.
68. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and onco-genic potential of the Met receptor tyrosine kinase. Oncogene 1994;9:2019-27.
69. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signal-ing and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
70. Komada M, Kitamura N. The cell dissociation and motility triggered by scatter factor/hepa-tocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor. Oncogene 1993;8:2381-90.
71. Weidner KM, Sachs M, Birchmeier W. The met receptor tyrosine kinase transduces motility, proliferation and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 1993;121:145-54.
72. Zhu H, Naujokas MA, Park M. Receptor chimeras indicate that the met tyrosine kinase mediates the motility and morphogenic responses of hepatocyte growth/scatter factor. Cell Growth Differ 1994;5:359-66.
73. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-13.
74. Igawa T, Kanda S, Kanetake H. Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells. Biochem Biophys Res Commun1991;174: 831-8.
75. Kan M, Zhang G, Zarnegar R, et al. Hepatocyte growth factor/hepatopoietin A stim-ulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchy-mal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE. Biochem Biophys Res Commun1991; 174:331-7.
76. Montesano R, Matsumoto K, Nakamura T, et al. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991;67:901-8.
77. Zhuang Z, Park W, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant met allele in hereditary papillary renal carcinomas. Nat Genet1998;20:66-9.
78. Jeffers M, Koochekpour S, Fiscella M, et al. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene 1998;17:2691-700.
79. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the Met tyrosine receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50.
80. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
81. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of met protooncogene. Cancer Cell 2003;3:347-61.
82. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomy-omas and renal cell cancer. Proc Natl Acad Sci U S A 2001;98:3387-92.
83. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell can-cer. Nat Genet 2002;30:406-10.
84. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet2003;12:1241-52.
85. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106.
86. Wei MH, Toure O, Glenn GM, et al. Novel mutation in FH and expansion of the spec-trum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006;43:18-27.
87. Alam NA, Olpin S, Leigh IM. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br J Dermatol 2005; 153:11-7.
88. Kiuru M, Launonen V, Hietala M, et al. Familial cutaneous leiomyomatosis is a two hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001;159:825-9.
89. Birt AR, Hogg GR, Dubé J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977;113:1674-7.
90. Nickerson ML, Warren MB, Toro J, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002;2:157-64.
91. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dubé syndrome, a genoder-matosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001;69:876-82.
92. Khoo SK, Bradley M, Wong FK, et al. Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene2001;20:5239-42.
93. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signal-ing. Proc Natl Acad Sci U S A 2006;103:15552-7.
94. Linehan WM, Walther MM, Zbar B, et al. The genetic basis of cancer of the kidney. J Urol 2003;170:2163-72.
95. Roth JS, Rabinowitz AD, Benson M, et al. Bilateral renal cell carcinoma in the Birt-Hogg-Dubé syndrome. J Am Acad Dermatol 1993;29:1055-6.
96. Pavlovich CP, Hewitt S, Walther MM, et al. Renal tumors in the Birt-Hogg-Dubé syn-drome. Am J Surg Pathol 2002;26:1542-52.
97. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 2005;76:1023-33.
98. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 2005; 97:931-5.
99. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
100. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 2006;24:5593-600.
101. Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol2004;287:F1-6.
102. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
103. Amin MB, Tamboli J, Javidan H, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26: 281-91.
104. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immuno-histochemical study of 105 tumors. Mod Pathol 1997;10:537-44.
105. Lubensky IA., Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal car-cinomas with c-MET mutations share a distinct morphological phenotype. Am J Pathol 1999;155:517-26.
106. Kovacs G. The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours. World J Urol 1994;12:64-8.
107. Phillips JL, Pavlovich CP, Walther M, et al. The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Curr Opin Urol 2001; 11:463-9.
108. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-onco-gene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
109. Glukhova L, Lavialle C, Fauvet D, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcino-mas: increased copy number and overexpression of the MET proto-oncogene. Oncogene 2000;19:754-61.
110. Zambrano NR, Lubensky IA, Merino MJ, et al. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol1999;162:1246-58.
111. Shipley JM, Birdsall S, Clark J, et al. Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenet Cell Genet 1995;71:280-4.
112. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med 2005;353:2477-90.
113. Linehan WM, Zbar B. Focus on kidney cancer. Cancer Cell 2004;6:223-8.
114. Da Silva NF, Gentle D, Hesson LB, et al. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet 2003;40:820-4.
115. Khoo SK., Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003;63:4583-7.
116. Lam JS, Leppert JT, Figlin RA, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005;66:1-9.